

Bone Mineral Density in Children with Relapsing Nephrotic Syndrome

M. Basiratnia, M.H. Fallahzadeh,
A. Derakhshan, G. Hosseini-Al-Hashemi

Abstract

Background: Given the high relapse rate of disease in children with steroid dependent nephrotic syndrome and the osteoporotic effect of long periods of steroid therapy, this survey was performed to find the bone mineral status of these patients.

Methods: Bone mineral density and content (BMD and BMC) were measured using Dual energy X-ray absorptiometry in 37 nephrotic children, six girls and 31 boys aged from four to 21-yrs, as patient group and 37 age and sex-matched healthy individuals as control group. Historical data were collected by chart review.

Results: As compared to the control group, the patients were shorter in stature. The percentage of BMC of lumbar and BMD of femoral bones of the patients was significantly lower than control group. According to the Warner method, 12% of the patients were osteoporotic and the BMD of their femoral and lumbar bones was inversely correlated with cumulative steroid dose.

Conclusion: Bone loss can occur in some steroid-dependent nephrotic patients, especially those with low age of onset and those with longer duration of the disease and higher cumulative dose of steroid. Therefore, measurements of BMD and BMC could be recommended, at least, for the selected patients.

Iran J Med Sci 2006; 31(2): 82-86.

Keywords • BMD • nephrotic syndrome • osteoporosis • corticosteroid

Introduction

Steroid-dependent nephrotic syndrome (SDNS) is one of the most common causes of childhood referral to pediatric nephrologists, which due to its relapsing course, long term steroid treatment is inevitable.¹ Corticosteroids directly and indirectly contribute to derangements in calcium and bone metabolism with frequent loss of vitamin D metabolites in the urine.²

Although bone demineralization is a well-known side effect of long term corticosteroid therapy, previous studies showed conflicting results in relation to SDNS.³⁻¹² It is not clear how and in which group of patients preventive measures should be taken to protect bone mineralization. Therefore, this study was designed to determine the bone mineral status of the nephrotic patients compared to age and sex-matched healthy individuals

Department of Pediatric Nephrology,
Nemazee Hospital,
Shiraz University of Medical Sciences,
Shiraz, Iran.

Correspondence:

Mitra Basiratnia MD,
Department of Pediatric Nephrology,
Nemazee Hospital,
Shiraz University of Medical Sciences,
Shiraz, Iran.

Tel: +98 711 2295136

Fax: +98 711 6265024

E-mail: m_basiratnia@yahoo.com

as control group as well as to what is considered normal for their body size and pubertal stage, to provide preventive and therapeutic measures for patients with SDNS.

Patients and Methods

The present study comprised patients who were followed in pediatric nephrology clinic as steroid-dependent or frequently relapsing nephrotic syndrome. Steroid-dependent nephrotic syndrome was defined as two consecutive relapses during corticosteroid treatment or within 14 days of its cessation.¹³ Those who had two or more relapses within six months of initial response or four or more relapses within any 12 months period, were considered as frequent relapsers.¹³

Bone mineral density and content (BMD and BMC) of lumbar L₁-L₄ and femoral neck were assessed in 37 patients with SDNS and in 37 age and sex-matched healthy students selected from Shiraz primary and secondary schools after describing the study and taking a written consent from them or their parents. BMD and BMC were measured by Dual Energy X-ray absorptiometry (DEXA, Lunar DPX, General Electric; USA).

All patients had normal glomerular filtration rate (Schwartz formula) and were treated with prednisolone (60mg/m²/day) for four weeks at the onset, followed by a single dose of 40 mg/m² on alternate days for tapering off during six weeks. The relapses were treated with prednisolone (60 mg/m²/day) until the urine was protein-free for three days, when it was continued with 40 mg/m² every other day for six to eight weeks. However, some patients with relapse were maintained on low daily dose of prednisolone for variable time periods. Other drugs, like levamisole, cyclophosphamide and cyclosporine were used for 18, 8 and 7 patients, respectively. None of the patients received calcium or vitamin D. In a 21-yr-old patient, interpretation of data was based on WHO criteria. As four patients were not cooperative in positioning their legs during the procedure for femoral neck, the assessment of BMD was thus made on 33 patients for the femoral region and 37 patients for the lumbar area. The Warner method,¹⁴ was used to compare the lumbar BMC of 32 patients with that of the control group aging from six to 18 yrs.

Statistical analysis

Data are presented as Mean±SD. Statistical analysis was performed using paired Students t-test for comparison of quantitative variables and Pearson correlation for determining the

relationship between the variables and $P < 0.05$ was considered significant.

Results

The patients under study comprised six girls and 31 boys, with the means of age and ages at the onset of nephrotic syndrome being 11.9±3.9 yrs and 6.4±3.6 yrs respectively. Other characteristics of the patients are shown in Table 1.

Table 1: Clinical characteristics of the patients

Characteristic	Mean±SD	Range
# of relapses	6.7±5.7	2-21
Total dose (mg)	13971±11858	1987-57930
Age (yr)	11.9±3.9	4-21
Age at onset (yr)	6.4±3.6	2-14
Duration (yr)	5.3±4.2	0.7-18

As shown in Table 2, the patients were significantly shorter in stature than the control individuals. According to Table 2, the BMD of L₁-L₄ was the same in both groups; whereas their BMC and %BMC of L₁-L₄ were significantly different. A significant difference was found between patients and control group in regard to the BMD of femoral neck. Considering WHO criteria, a femoral and lumbar area T scores of less than 2.5 standard deviation, favoring osteoporosis, was found in one patient who was over 18-yr-old.¹⁵

Table 2: Comparison of mean±SD of weight, height, BMI, BMD and BMC of patients and control groups

Characteristics (n)	Patients	Control
Height (cm) (37)	142.1±15.5	149.5±19.2*
Weight (kg) (37)	38.4±13.3	41.4±15.6
BMI (kg/m ²) (37)	17.7±12.8	18.9±13.8
Femur BMD (g/cm ²) (32)	0.8±0.1	0.9±0.2*
L ₁ -L ₄ BMD (g/cm ²) (36)	0.7±0.1	0.8±0.2
L ₁ -L ₄ BMC (%) (32)	104±16	111.5±14.6*
L ₁ -L ₄ BMC (g) (32)	25.5±10.5	31.0±16.3*

BMI= body mass index; BMD= bone mineral density; BMC= bone mineral content, L= lumbar
* data of the patient group is significantly different from control at $P < 0.05$

BMD of the femoral and lumbar area were significantly lower in patients with higher cumulative steroid doses (Fig 1 and 2). In contrary to the duration of disease and the age at onset, we found no correlation between the number of relapses and the prediction of osteoporosis. No correlation was found between cyclosporine treatment and BMD of the femoral and lumbar area in either the patients or the control group. Although, 12% of the patients were osteoporotic, no difference was found between BMD of femoral and lumbar bones in relation to the schedule of steroid therapy (daily or alternate days).




Fig. 1: Correlation between cumulative steroid dose and differential bone densitometry (DBDF) of femoral BMD of patient and control groups.




Fig. 2: Correlation between cumulative steroid dose and lumbar BMD differential bone densitometry (DBDL) of patients and control groups.

Discussion

The present study showed that osteoporosis found in 12% of the patients was correlated with lower age of disease onset, longer duration of the disease and higher cumulative steroid dose. The adverse effects of corticosteroid on bone mineralization are well established, and are the subjects of several studies with variable results.³⁻¹²

In our study decreased BMD of the femoral area and BMC of lumbar bones were apparently in contrast to what was found by

Esbjorner et al.⁹ In their cross-sectional study, analysis of nine children treated with a high total steroid dose showed no difference in BMC between the patients and the control group. This discrepancy might be due to the fact that all but one of the patients in the Esbjorner study were in remission phase and were not taking corticosteroid during their investigation.⁹ However, only nine patients were free from steroids in the course of our study. Although, Kano and coworkers showed normal BMD at 16 weeks after steroid withdrawal in the first episode of nephrotic syndrome.¹⁶ However, there are no substantiated data in regards to normalization of BMD and BMC in patients receiving different and multiple steroid doses. Even though, in Esbjorner et al. study no difference was found between BMD of the patients and control groups, reduced bone turnover and lower growth rate were observed in patients compared to the controls.⁹

Our results also contrasted with those of Morin and his colleagues who observed no changes in BMD in 29 children treated with corticosteroid.¹⁷ Also BMC was not reduced in 24 patients with steroid sensitive nephrotic syndrome treated for one, three and six years with corticosteroid.⁶ In the latter study, the patients received calcium and vitamin D, which might have counteracted the demineralization effect of steroid.⁶ Recently, Leonard and coworkers reported that glucocorticoid therapy was not associated with bone loss at the lumbar area after correction for body mass index.¹⁸ However, they were in agreement with the effect of steroid on bone mineral and quality not captured by bone mineral content.¹⁸ The results of other investigations supported our findings of bone loss in nephrotic patients.^{8,19,20}

The assessment of BMD in children with acquired glomerular disease treated with corticosteroid showed a significant bone loss even with an alternative dosage schedule.²⁰ In these patients, bone density was influenced by the steroid treatment and not by the glomerular diseases.²⁰ Lettgen and his colleagues assessed 26 patients with SDNS by quantitative computed tomography and found that bone loss was positively correlated with steroid dosage.⁸ Reugseggar found bone losses in asthmatic patients even with alternate days of steroid therapy.¹⁹

Osteoporosis is one the important side effects of steroid treatment and the incidence of steroid-induced osteoporosis was reported to be 30-50% in patients with long-term therapy.²¹ We found that higher cumulative steroid dose is associated with lower BMD and the cause is multifactorial. Corticosteroids directly inhibit osteoblasts and consequently the synthesis of osteoid.²² They also decrease intestinal and

renal calcium absorption with the resultant secondary hyperparathyroidism leading to increased bone resorption.²¹

Our observation indicated that the lower age at the onset and the longer duration of the disease were well correlated with greater bone demineralization. This correlation was more pronounced with the lumbar area than with the femoral bone. Lower age and longer duration of the disease were associated with more steroid consumption and consequently more bone loss, however, this is contrasting the results of Gulati et al. showing that older age at the onset was associated with lower BMD.²³ The reason seeing these discrepancies is not obvious but it is suggested that lower BMD could be caused by age-related changes in hormonal, calcium and vitamin D metabolism and a more active growth phase.

No difference was found between BMD of femoral and lumbar bones, resulting from the steroid therapy schedules (daily or alternate day). Although this was in concordance to the Polito and colleagues' study who found that alternate day prednisolone therapy did not affect BMC significantly as compared to control group,⁶ but the duration of the disease in their patients was shorter (three yrs) and they used calcium and vitamin D supplements.

In seven patients who received cyclosporine together with steroid, the changes in their bone were not different with those of steroid-treated group. Although, the role of cyclosporine on bone status is still controversial,^{24,25} some reports are in favour,²⁴ and the others are against the bone demineralization effect of cyclosporine.²⁵

Conclusion

Bone loss will occur in some patients with steroid-dependent nephrotic syndrome, especially with lower age of onset, longer duration of disease and higher cumulative dose of steroid. Therefore bone mineral density and content measurements are recommended, at least, for selected patients.

References

- 1 Niaudet P. Steroid-sensitive idiopathic nephrotic syndrome in children. Avner E, Harmon WE, Niaudet P. In *Pediatric Nephrology*. Philadelphia. 5th edition. Lippincott Williams & Wilkins; 2004. p. 543-56.
- 2 Grymonprez A, Proesmans W, Van Dyck M, et al. Vitamin D metabolites in childhood nephrotic syndrome. *Paediatr Nephrol* 1995; 9: 278-81.
- 3 Lukert BP, Raisz LG. Glucocorticoid-

- induced osteoporosis: Pathogenesis and management. *Ann Intern Med* 1990; 112: 352-64.
- 4 Lukert BP, Raisz LG. Glucocorticoid induced osteoporosis. *Rheum Dis Clin North Am* 1994; 20: 629-50.
- 5 Hahn TJ, Halstead LR, Teitelbaum SL, et al. Altered mineral metabolism in glucocorticoid induced osteopenia. Effect of 25-hydroxy Vitamin D administration. *J Clin Invest* 1979; 64: 655-65.
- 6 Polito C, LaManna A, Todisco N, et al. Bone mineral content in nephrotic children on long-term, alternate-day prednisone therapy. *Clin Pediatr (Phila)* 1995; 34: 234-6.
- 7 Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: three year follow up. *J Rheumatol* 1996; 23: 995-1000.
- 8 Lettgen B, Jeken C, Reiners C. Influence of steroid medication on bone mineral density in children with nephrotic syndrome. *Pediatr Nephrol* 1994; 8: 667-70.
- 9 Esbjorner E, Arvidsson B, Jones IL, et al. Bone mineral content and collagen metabolites in children receiving steroid treatment for nephrotic syndrome. *Acta Paediatr* 2001; 90: 1127-30.
- 10 Fujita T, Satomura A, Hidaka M, et al. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high dose glucocorticoid and one-cycle etidronate therapy. *Calcif Tissue Int* 2000; 66: 195-9.
- 11 Sierra RI, Specker BL, Jimenez F, et al. Biochemical bone markers, bone mineral content and bone mineral density in rats with experimental nephrotic syndrome. *Ren Fail* 1997; 19: 409-24.
- 12 Takeda Y. Evaluation of bone mineral turns over in children with nephrotic syndrome. The implication of original disease and the effects of corticosteroids on bone metabolism. *Nippon Jinzo Gakkai Shi* 1993; 35: 705-13.
- 13 Clark AG, Barratt TM. Steroid responsive nephritic syndrome. Barratt TM, Avner ED, Harmon WE. In *Pediatric Nephrology*. Baltimore. 4th edition. Lippincott Williams & Wilkins; 1999. p. 731-43.
- 14 Warner JT, Cowan FJ, Dunstan FD, et al. Measured and predicted bone mineral content in healthy boys and girls aged 6-18 years: adjustment for body size and puberty. *Acta paediatr* 1998; 87: 244-9.
- 15 Faulkner KG. Update on bone density measurement. *Rheum Dis Clin North Am* 2001; 27: 81-99.

- 16 Kano K, Hoshi M, Nishikura K, et al. Skeletal effects of short-term prednisolone therapy in children with steroid-responsive nephrotic syndrome. *Clin Exp Nephrol* 2001; 5: 40-3.
- 17 Morin D, Kotzki PO, Dalla Vale P, et al. Bone mineral density in children with steroid sensitive nephrotic syndrome. *Pediatr Nephrol* 1996; 10: C147A.
- 18 Leonard MB, Feldman HI, Shults J, et al. Long term, high dose glucocorticoids and bone mineral content in childhood glucocorticoid sensitive nephrotic syndrome. *N Engl J Med* 2004; 351: 868-75.
- 19 Ruegsegger P, Medici TC, Anliker M. Corticosteroid induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. *Eur J Clin Pharmacol* 1983; 25: 615-20.
- 20 Chesney RW, Mazess RB, Rose P, et al. Effect of prednisone on growth and bone mineral content in childhood glomerular disease. *Am J Dis Child* 1978; 132: 768-72.
- 21 Cunnane G, Lane NE. Steroid induced osteoporosis in systemic lupus erythematosus. *Rheum Dis Clin North Am* 2000; 26: 311-29.
- 22 Dempster DW. Bone histomorphometry in glucocorticoid induced osteoporosis. *J Bone Miner Res* 1989; 4: 137-41.
- 23 Gulati S, Godbole M, Singh U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? *Am J Kidney Dis* 2003; 41:1163-9.
- 24 Thiebaud D, Krieg MA, Gillard-Berguer D, et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. *Eur J Clin Invest* 1996; 26: 549-55.
- 25 Durieux S, Mercadal L, Orcet P, et al. Bone mineral density and fracture prevalence in long term kidney graft recipients. *Transplantation* 2002; 74: 496-500.